AndhraNews.net
Home » Features » Film Directors » John Woo

John Woo


About John Woo

John Woo is a film director popular for his direction of the movie Mission: Impossible.

John Woo in News

Twentieth Century Fox Names Sirena Liu Managing Director of China Office
Business Wire IndiaTwentieth Century Fox Chairman and CEO, Jim Gianopulos, named Sirena Liu to the newly created position of Managing Director, China.

Arts Expert Leah Selakovic Attends Singapore International Film Festival
Arts expert Leah Selakovic extended a warm welcome to legendary French actress, Juliette Binoche, at the Fundraising Dinner Olga Iserlis organized as part of the 25th Singapore International Festival earlier this month. The two women shared a table and a few laughs at the glamorous event, which was hosted by internationally acclaimed celebrity chef, Wolfgang Puck

Zebra Technologies Strengthens Leadership Across APAC
Zebra Technologies Corporation (NASDAQ: ZBRA), a recognized global leader in products and solutions that extend real-time visibility into business operations, today announced new strategic appointments across Asia Pacific (APAC), to bolster the company's leadership in the region.

Building Turbines Completes First LED Lighting Installation for Toyko One, Sushi and Gourmet Cuisine Buffet
Building Turbines, Inc. (PINKSHEETS: BLDW), through Green City Planet, LLC, a fully owned subsidiary of Building Turbines, Inc., is pleased to announce the completion of another major LED Lighting installation with a quality restaurant chain; Tokyo One located in Houston Texas.

Indian Comic Books Take off with ‘Graphic India’ A New Digital Comic Book Platform for Creators
Liquid Comics, which owns one of the world’s largest comic book libraries based on Indian characters by Indian creators, announced today the launch of Graphic India, a new digital platform to promote comic books in India and showcase young artists and writers in the country.

Seventh Edition of Entertainment Expo Hong Kong Opens Next Month
Entertainment Expo Hong Kong, Asia's leading entertainment industry gathering, gets underway next month with an expanded lineup of 10 international events, including FILMART, which is expected to attract a record number of exhibitors

NuPathe Announces Third Quarter 2010 Financial Results and Recent Operational Highlights
NuPatheInc. (NASDAQ: PATH), a specialty pharmaceutical company focused on thedevelopment and commercialization of branded therapeutics for diseases ofthe central nervous system, including neurological and psychiatricdisorders, today announced financial results for the quarter endedSeptember 30, 2010 and recent operational highlights.

NuPathe to Present at the Lazard Capital Markets 7th Annual Healthcare Conference
NuPathe Inc

Gillette Children's Specialty Healthcare Selects Carefx Corp. and Indigo Identityware for Interoperability and Secure Workflow Management
Gillette Children's Specialty Healthcare has selected Carefx Corp. and Indigo Identityware's solutions to provide caregivers the most secure, efficient and powerful solution to meet their context management and clinical workflow needs.

Cornerstone Therapeutics Reports Third Quarter 2010 Financial Results
Cornerstone Therapeutics Inc. (NASDAQ: CRTX)today reported net income of $0.8 million, or $0.03 per diluted share, forthe third quarter of 2010, compared to a net loss of $0.5 million, or($0.03) per diluted share, for the third quarter of 2009. On a non-GAAPbasis, net income was $3.8 million, or $0.15 per diluted share, for thethird quarter of 2010, compared to non-GAAP net income of $1

NuPathe to Report Third Quarter 2010 Results and Hold Conference Call on Thursday, November 11, 2010
NuPathe Inc. (NASDAQ: PATH), a specialty pharmaceutical company focused on the development and commercialization of branded therapeutics for diseases of the central nervous system, including neurological and psychiatric disorders, will report third quarter 2010 results on Thursday, November 11, 2010 after the close of the U.S. financial markets. NuPathe will also host a conference call at 4:30 p

NuPathe Submits Zelrix NDA for the Treatment of Migraine
NuPathe Inc. (NASDAQ: PATH), a specialty pharmaceutical company focused on the development and commercialization of branded therapeutics for diseases of the central nervous system, today announced that the company submitted a New Drug Application (NDA) for Zelrix™ to the U.S. Food and Drug Administration (FDA)

Comment on this story

Share